Requirements for a treatment planning system for radioimmunotherapy.
Cancer-seeking antibodies carrying radionuclides can, in theory, be very powerful agents for the radiotherapy of cancer. However, as with all radiotherapy, the undesired dose to critical normal organs is the limiting factor that determines success or failure. The distribution of radiation dose in cancer and noncancer tissue is highly dependent on choices the therapist can make: choices of the antigens to be targeted, choices of the antibodies or antibody fragments to be used, choices of radionuclides, of amounts, of timing, and other electives. New technologies, especially of monoclonal antibody production, make the options myriad. Optimization of this therapy depends on a foreknowledge of the radiation dose distributions to be expected. The necessary data can be acquired by established tracer techniques, in individual patients, for particular treatment selections. These tracer techniques can now be implemented by advanced equipment for quantitative, tomographic radionuclide imaging and strengthened by dynamic modeling of the physiological parameters which govern radionuclide distribution, and hence radiation dose distribution.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000912:Antibodies, Neoplasm / Q000008:administration & dosage*; D003300:Copper / Q000008:administration & dosage; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D010347:Patient Care Planning / Q000379:methods*; D011868:Radioisotopes / Q000008:administration & dosage*; D014055:Tomography, Emission-Computed
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D003300:Copper